519 related articles for article (PubMed ID: 15265259)
1. Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey--Phase III.
MacGregor EA; Brandes J; Eikermann A; Giammarco R
Curr Med Res Opin; 2004 Jul; 20(7):1143-50. PubMed ID: 15265259
[TBL] [Abstract][Full Text] [Related]
2. Patient preference for triptan formulations: a prospective study with zolmitriptan.
Dowson A; Bundy M; Salt R; Kilminster S
Headache; 2007 Sep; 47(8):1144-51. PubMed ID: 17883519
[TBL] [Abstract][Full Text] [Related]
3. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey.
MacGregor EA; Brandes J; Eikermann A
Headache; 2003 Jan; 43(1):19-26. PubMed ID: 12864754
[TBL] [Abstract][Full Text] [Related]
4. The impact of migraine on work, family, and leisure among young women -- a multinational study.
Dueland AN; Leira R; Burke TA; Hillyer EV; Bolge S
Curr Med Res Opin; 2004 Oct; 20(10):1595-604. PubMed ID: 15462692
[TBL] [Abstract][Full Text] [Related]
5. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
Gawel M; Aschoff J; May A; Charlesworth BR;
Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
[TBL] [Abstract][Full Text] [Related]
6. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.
Bigal ME; Serrano D; Reed M; Lipton RB
Neurology; 2008 Aug; 71(8):559-66. PubMed ID: 18711108
[TBL] [Abstract][Full Text] [Related]
7. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial.
Dowson AJ; Charlesworth BR; Green J; Färkkilä M; Diener HC; Hansen SB; Gawel M;
Headache; 2005 Jan; 45(1):17-24. PubMed ID: 15663608
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and patterns of medication use of migraneurs in Latin America from 12 cities in 6 countries.
Morillo LE; Alarcon F; Aranaga N; Aulet S; Chapman E; Conterno L; Estevez E; Garcia-Pedroza F; Garrido J; Macias-Islas M; Monzillo P; Nunez L; Plascencia N; Rodriguez C; Takeuchi Y;
Headache; 2005 Feb; 45(2):118-26. PubMed ID: 15705116
[TBL] [Abstract][Full Text] [Related]
9. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey.
Lucas C; Géraud G; Valade D; Chautard MH; Lantéri-Minet M
Headache; 2006 May; 46(5):715-25. PubMed ID: 16643573
[TBL] [Abstract][Full Text] [Related]
10. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective.
Vicente-Herrero T; Burke TA; Laínez MJ
Curr Med Res Opin; 2004 Nov; 20(11):1805-14. PubMed ID: 15537481
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.
Diamond ML; Cady RK; Mao L; Biondi DM; Finlayson G; Greenberg SJ; Wright P
Headache; 2008 Feb; 48(2):248-58. PubMed ID: 18234046
[TBL] [Abstract][Full Text] [Related]
12. Impact of migraine and migraine therapy on productivity and quality of life.
Solomon GD; Santanello N
Neurology; 2000; 55(9 Suppl 2):S29-35. PubMed ID: 11089517
[TBL] [Abstract][Full Text] [Related]
13. Pain among children and adolescents: restrictions in daily living and triggering factors.
Roth-Isigkeit A; Thyen U; Stöven H; Schwarzenberger J; Schmucker P
Pediatrics; 2005 Feb; 115(2):e152-62. PubMed ID: 15687423
[TBL] [Abstract][Full Text] [Related]
14. Predictors of adherence to triptans: factors of sustained vs lapsed users.
Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
[TBL] [Abstract][Full Text] [Related]
15. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study.
Láinez MJ; López A; Pascual AM
Headache; 2005; 45(7):883-90. PubMed ID: 15985105
[TBL] [Abstract][Full Text] [Related]
16. [The application of migraine disability assessment questionnaire (MIDAS)].
Hung PH; Fuh JL; Wang SJ
Acta Neurol Taiwan; 2006 Mar; 15(1):43-8. PubMed ID: 16599285
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes.
Silberstein SD; Cady RK; Sheftell FD; Almas M; Parsons B; Albert KS
Headache; 2007 May; 47(5):673-82. PubMed ID: 17501848
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
Chen LC; Ashcroft DM
Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569
[TBL] [Abstract][Full Text] [Related]
19. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
[TBL] [Abstract][Full Text] [Related]
20. Part III: the convenience of, and patient preference for, zolmitriptan orally disintegrating tablet.
Dowson AJ; Almqvist P
Curr Med Res Opin; 2005; 21 Suppl 3():S13-7. PubMed ID: 16083519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
